Onco Actu du 7 mars 2017

	3.1.1 Tabac - e-cigs
Global E-Cigarette Market Size, Share, Development, Growth and Demand Forecast to 2022 [ResearchAndMarkets] The global e-cigarette (electronic cigarette) market is expected to witness a CAGR of 16.6% during the forecast period, to reach $27,670 million by 2022.
	3.2 Prévention - Obésité
The Microbiome and Human Obesity: Wait a Minute [In the Pipeline] This is something to keep in mind when you hear about the marvels that can be produced through machine learning. I actually have little doubt that marvels are possible through such routes, but “garbage in, garbage out” is a law of the universe that no one has ever been able to repeal.
	4.12 Biopsies liquides
OncoCyte says study confirms accuracy of lung cancer blood test [Reuters] OncoCyte said it was preparing for a commercial launch of the test as early as the second half of this year and expects it will be the first product of its kind for lung cancer to reach the market.
	5. Traitements
A new way to reset gene expression in cancer cells shows promise for leukemia treatment [The Rockefeller University] New findings from Rockefeller University researchers could guide the development of potent combination therapies that deliver more effective and durable treatment of leukemia. In recent work published in Nature, they show it’s possible to deactivate cellular programs involved in tumor growth by disrupting a protein that regulates genes.
	5.12.5 Immunothérapies - Pharma
Advaxis gets green light for trial of Amgen-partnered neoantigen cancer vaccine [FierceBiotech] Advaxis' approach is based on the use of an antigen delivery technology that uses a bacteria carrier to present multiple neoantigens to the immune system, which the company says stimulates both cell and antibody responses against tumor cells.
Race Tightens for Next Wave of Cancer Drugs [Wall Street Journal] Epacadostat, taken as a pill, is designed to block IDO1 on and around tumor cells to allow the immune system to shrink tumors. Incyte’s research on the IDO1 program began in 2005, at a time when few people thought immunotherapy could effectively fight cancer.
	5.2 Pharma
Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma [Exelixis] A pivotal phase 3 trial (CELESTIAL) of cabozantinib is ongoing in patients with advanced HCC, and Exelixis has guided that data from the trial are expected in 2017.
TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK [EndPoints] Investigators say that TG-1101 (ublituximab), their anti-CD20 monoclonal antibody, plus Imbruvica beat Imbruvica alone in treating high-risk chronic lymphocytic leukemia.
TG Therapeutics' leukemia drug clears hurdle in key study [Reuters] The trial was designed to evaluate whether adding ublituximab would induce a statistically significant improvement in overall response rate by at least 20 percent between the two groups of patients.
	5.3 Traitements - FDA, EMA, NICE...
FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine [Seattle Genetics] Going forward, additional risk mitigation measures will be implemented in all vadastuximab talirine studies, including revised eligibility criteria and stopping rules for veno-occlusive disease (VOD).
Seattle Genetics to Resume Leukemia Drug Trials After FDA Lifts Hold [Xconomy] SeaGen now plans to resume two Phase 1 trials in adults with AML and also start a randomized Phase 2 study evaluating the drug in combination with chemotherapy, the standard of care.
FDA lifts its hold on vadastuximab talirine after Seattle Genetics adds new safeguards [EndPoints] Moving forward, the biotech says it’s implementing added risk mitigation measures in all vadastuximab talirine studies, including “revised eligibility criteria and stopping rules for veno-occlusive disease.”
FDA lifts hold on Seattle Genetics drug trials [Reuters] The FDA imposed the clinical hold in December after the company reported the deaths of four people in trials testing the experimental cancer drug, vadastuximab talirine. Seattle Genetics said on Monday the clinical hold was resolved through a comprehensive study evaluating more than 300 patients and amendments to further enhance safety.
	5.6 ESMO
Targeted Anticancer Therapies (TAT) Congress Becomes an Annual ESMO Event [ESMO] Starting in 2018, the TAT Congress, considered the “home of phase 1 in oncology,” will take place annually in Europe, with next year’s congress organised in March in Paris, France.
	5.9 AACR
New AACR Social Media Policies for Scientific Meetings Strive for Balance [Cancer Research Catalyst] Oral presenters may label any or all slides in their presentations with “DO NOT POST.” Similarly, poster presenters may label their posters with “DO NOT POST.”
	6. Lutte contre les cancers
Measuring the quality of cancer care [Healthcare Economist] So what are the options? Provide uber-detailed qualty metrics for each individual tumor type (or even within tumor type)? Measure quality of care broadly? Or give up on the whole top-down quality measurement endeavor.
Exercise better than drugs for cancer fatigue [Reuters] Researchers examined data from 113 previously published studies involving more than 11,500 cancer patients with fatigue. Patients were randomly assigned to treat their exhaustion with exercise or psychotherapy, or both, or with drugs.
	6.1 Observation
Soy tied to longer life after breast cancer [Reuters] For the current study, researchers examined data on 6,235 U.S. and Canadian women with breast cancer. More than half of the women were followed for at least nine years.
	6.10.1 Politiques (USA)
Federal right-to-try legislation undermines patient protection and drug testing [STAT] Between January 2005 and December 2014, the FDA received 8,922 new applications for expanded access, and approved 99.3 percent of them. This review is not simply a rubber stamp — the agency often provides important feedback on dosing, safety monitoring, and informed consent documentation.
	6.5 Médecines alternatives
The Texas Medical Board lets Stanislaw Burzynski off lightly: A cautionary tale of the failure of regulating medicine [Science-Based Medicine] After three years and countless twists and turns, the final decision by the Texas Medical Board on the sanctions to be imposed on Houston cancer quack Dr. Stanislaw Burzynski were announced on Friday. Sadly, they were not enough. The Burzynski saga should serve as a cautionary tale that the regulation of physicians and medicine is too lax, not too strict.
	6.7 DMP, Big Data & applis
Mark Cuban Asked And I Respond: Will This Company Transform The Economics and Results of Healthcare? [Dr. Len] For me, the key to making that kind of transformation means putting the people at the center of the health technology universe. Right now, from where I sit, I feel—as a patient and consumer of health care—like I am an afterthought in this juggernaut we call health care information technology.
	6.8 Communication
Null but not void: Why health journalists need to stop ignoring negative studies [HealthNewsReview] This impulse to cover positive findings — no matter how shaky — and neglect stronger null findings pervades medical journalism. It’s particularly obvious with statins, as pharmaceutical companies push for new uses of these old drugs in order to expand their market.
	6.9 Controverses
Soon-Shiong’s company stock falls 23 percent following STAT report [STAT] Attorneys at New York-based Rosen Law Firm on Monday announced they were investigating “potential securities claims” stemming from STAT’s reports on behalf of the company’s investors and put out a request for NantHealth investors to contact them. Such calls rarely result in a class action suit.
How the world’s richest doctor gave away millions — then steered the cash back to his company [STAT] The University of Utah deal — laid out in contracts obtained by STAT through a public records request — illustrates how Soon-Shiong boosted his business through his philanthropy. He has been accused of doing just that in at least two legal filings, but the Utah contracts offer the first concrete example, spelled out in black and white.